Paper · 19459166

Histone deacetylase inhibitors: Potential in cancer therapy.

Marks PA and 1 other. J Cell Biochem, 2009. Cited by 586 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Histone deacetylase inhibitors: Potential in cancer therapy. Papers, record 19459166. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19459166

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Histone deacetylase inhibitors: Potential in cancer therapy.; PubMed
Journal: J Cell Biochem; PubMed
Year: 2009; PubMed
Publication types: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/19459166/; PubMed
DOI: https://doi.org/10.1002/jcb.22185; PubMed
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC2766855/; PubMed
The journal: https://conductscience.org/library/journal-index/8205768; PubMed
Citations, by iCite: 586; iCite
Relative citation ratio, by iCite: 13.7; iCite
Revised in PubMed: 2025-05-29; PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename	Kind	ORCID iD
1	Marks PA	P A
2	Xu WS	W-S

Source PubMed

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Enzyme Inhibitors	Major topic
Histone Deacetylase Inhibitors	Major topic
Neoplasms	Major topic
Antineoplastic Agents
Cell Physiological Phenomena
Humans
Zinc

Source PubMed

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes it	Agency	Country	NIH project	Stated by	Source
P30 CA008748	NCI NIH HHS	United States	P30CA008748	PubMed and NIH	NIH RePORTER
P30CA08748-44	NCI NIH HHS	United States	P30CA087484	PubMed	NIH RePORTER

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References47

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	16,170,022	Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824.	Mol Cancer Ther	2005	https://conductscience.org/library/papers/16170022	PubMed
2	18,606,987	HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation.	Proc Natl Acad Sci U S A	2008	https://conductscience.org/library/papers/18606987	PubMed
3	17,594,194	Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma.	Expert Opin Investig Drugs	2007	https://conductscience.org/library/papers/17594194	PubMed
4	17,320,506	The epigenomics of cancer.	Cell	2007	https://conductscience.org/library/papers/17320506	PubMed
5	17,211,407	Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug.	Nat Biotechnol	2007	https://conductscience.org/library/papers/17211407	PubMed
6	16,951,198	Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha.	Cancer Res	2006	https://conductscience.org/library/papers/16951198	PubMed
7	17,694,093	Histone deacetylase inhibitors: molecular mechanisms of action.	Oncogene	2007	https://conductscience.org/library/papers/17694093	PubMed
8	17,643,370	HDAC6 modulates cell motility by altering the acetylation level of cortactin.	Mol Cell	2007	https://conductscience.org/library/papers/17643370	PubMed
9	15,846,093	Inhibitors of histone deacetylases alter kinetochore assembly by disrupting pericentromeric heterochromatin.	Cell Cycle	2005	https://conductscience.org/library/papers/15846093	PubMed
10	19,131,628	HDAC4 regulates neuronal survival in normal and diseased retinas.	Science	2009	https://conductscience.org/library/papers/19131628	PubMed

1 to 10 of 47

See all 47 references

Cited by338

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 586 citations.

PMID	Title	Journal	Year	In Papers	Source
42,773,415	Proteogenomic Analysis of HDAC4 and HDAC5 in Uveal Melanoma.	Mol Med	2026	https://conductscience.org/library/papers/42773415	PubMed
42,653,458	Thieno[3,2-d]pyrimidines in Anticancer Drug Discovery: Recent Advances in Drug Design and Molecular Targets.	Int J Mol Sci	2026	https://conductscience.org/library/papers/42653458	PubMed
42,355,593	Precision Medicine in Non-Hodgkin Lymphoma: Advances in BTK Inhibition, CD30-Directed Antibody-Drug Conjugates, and HDAC-Mediated Epigenetic Therapy with Pirtobrutinib, Brentuximab Vedotin, and Belinostat.	J Clin Med	2026	https://conductscience.org/library/papers/42355593	PubMed
42,250,622	Histone Deacetylase 7 protects against pathologic cardiac hypertrophy.	J Mol Cell Cardiol	2026	https://conductscience.org/library/papers/42250622	PubMed
42,197,051	Synbiotics as a Microbiome-Based Strategy in Colorectal Cancer.	Nutrients	2026	https://conductscience.org/library/papers/42197051	PubMed
42,127,228	From Scaffold to Therapy: Benzimidazole Pharmacophore Evolution in Breast Cancer Research.	Chem Biodivers	2026	https://conductscience.org/library/papers/42127228	PubMed
41,656,242	Advances in epigenetic therapy for esophageal cancer.	Clin Epigenetics	2026	https://conductscience.org/library/papers/41656242	PubMed
41,303,402	Garcinol as an Epigenetic Modulator: Mechanisms of Anti-Cancer Activity and Therapeutic Potential.	Int J Mol Sci	2025	https://conductscience.org/library/papers/41303402	PubMed
40,361,330	Current Treatment of Uveal Melanoma.	Cancers (Basel)	2025	https://conductscience.org/library/papers/40361330	PubMed
39,683,590	Butyrate as a Potential Modulator in Gynecological Disease Progression.	Nutrients	2024	https://conductscience.org/library/papers/39683590	PubMed

1 to 10 of 338

See all 338 cited by

Genes93

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Gene	NCBI Gene ID	Linked by	In Genes	Source
ABL1	25	PubTator's text mining	https://conductscience.org/library/genes/25	NCBI Gene
AKT1	207	PubTator's text mining	https://conductscience.org/library/genes/207	NCBI Gene
APAF1	317	PubTator's text mining	https://conductscience.org/library/genes/317	NCBI Gene
AR	367	PubTator's text mining	https://conductscience.org/library/genes/367	NCBI Gene
BAK1	578	PubTator's text mining	https://conductscience.org/library/genes/578	NCBI Gene
BAX	581	PubTator's text mining	https://conductscience.org/library/genes/581	NCBI Gene
BCL2	596	PubTator's text mining	https://conductscience.org/library/genes/596	NCBI Gene
BCL2L1	598	PubTator's text mining	https://conductscience.org/library/genes/598	NCBI Gene
BCL2L11	10,018	PubTator's text mining	https://conductscience.org/library/genes/10018	NCBI Gene
BCL2L2	599	PubTator's text mining	https://conductscience.org/library/genes/599	NCBI Gene

1 to 10 of 93

See all 93 genes

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/19459166

GET https://conductscience.org/api/papers/v1/19459166/references?page=2

API reference For AI assistants